Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04156893

RH Genotype Matched RBC Transfusions

To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 month and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States

Location status: Recruiting

Location contact

Stella Chou, MD

CONTACT

[email protected]

215-590-0947

Stella Chou, MD

PRINCIPAL_INVESTIGATOR

About this study

This is a Phase 1/2 trial in patients with Sickle Cell Disease requiring chronic red cell transfusions. RH genotyped donor units will be obtained from the New York Blood Center. Patients will be matched with donor units whose RH genotypes predict no foreign Rh protein exposure to the patient. This will provide red cell matching at a level above the current standard of care (serologic C, E, and K matching). Patients will receive RH matched red cells for the duration of their chronic transfusion therapy or up to three years, whichever is shorter. In the pilot phase, we have determined it is feasible to identify RH matched donor units for the patient's RH genotype for every scheduled transfusion. We will now continue to show feasibility as well as determine efficacy by monitoring Rh alloantibody formation.

For subjects with a history of stroke/recurrent transient ischemic attack or other indication who require tight control of Hb S, and RH genotyped blood is not available, standard of care serologic matched blood would be administered rather than delaying transfusion and risking higher Hb S level.

For all subjects, standard of care serologic matched blood would be administered rather than delaying transfusion beyond 7 days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects age >6 months
  • Diagnosis of SCD, all genotypes
  • Require a period of chronic red cell transfusion therapy
  • Subject/parental/guardian permission (informed consent) and if appropriate, child assent

Exclusion criteria

  • Rare RH genotype that would preclude identification of sufficient RBC units
  • Antigen negative requirements due to alloimmunization that would preclude identification of sufficient RBC units
  • Alloimmunized to D antigen
  • Rh alloimmunized patients for whom providing RH genotype matched blood would expose the patient to an antigen that would not be consistent with standard of care and blood bank protocols
  • Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures

Treatment and study plan

Red cell units that are genotype matched at the RHD and RHCE loci

Biological

Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.

Primary outcomes

  1. Determine the treatment efficacy by monitoring the rate of Rh alloimmunization

    Time frame: 3.5 years

    A primary objective is to determine whether providing RH genotype matched red cell units can reduce or prevent Rh alloimmunization.

  2. Determine the feasibility of identifying sufficient RH genotype matched units

    Time frame: 3.5 years

    A primary objective is to determine the feasibility of identifying sufficient RH genotype matched red cells for chronically transfused patients with SCD with varied RH genotypes. Approximately 20 RHD (Rhesus D) and 20 RHCE (Rhesus CE) variants have been observed in patients with SCD and will determine whether sufficient RH genotyped units can be matched to the patient's own RH genotype.

Secondary outcomes

  1. Determine the rate of non-Rh alloimmunization

    Time frame: 3.5 years

    A secondary objective is to determine the rate of antibody formation outside the Rh blood group system, such as anti-Kidd or -S/s.

Study contacts

Contact information is provided by the study sponsor or research team.

Stella Chou, MD

CONTACT

[email protected]

215-590-0947

Sponsors and collaborators

Lead sponsor

Children's Hospital of Philadelphia

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)
  • New York Blood Center

Registry information

Official study title

RH Genotype Matched Red Cell Transfusions for Patients With Sickle Cell Disease

Acronym: RBC

Important dates

Study start
2020
Primary completion
2029
Study completion
2029
First posted
Nov 8, 2019
Registry last updated
Apr 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.